Document is current
Any future updates will be listed below
-
Authors
Trapp, Nicholas T. https://orcid.org/0000-0003-0287-2964
Barbour, Tracy
Kritzer, Michael D.
Pottanat, Roger
Carreon, David
Chen, Leo
Brown, Joshua
Siddiqi, Shan
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (1K23MH125145, K23MH121657, R21MH126271)
McLean Hospital Maria Lorenz-Pope Fellowship
Defense Advanced Research Projects Agency (HR00112320037)
Brain and Behavior Research Foundation (31275)
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 4 August 2024
First Online: 15 August 2024
Declarations
:
: SHS is a scientific consultant for Magnus Medical. SHS is a clinical consultant for Acacia Mental Health, Kaizen Brain Center, and Boston Precision Neurotherapeutics. SHS has received investigator-initiated research funding from Neuronetics and BrainsWay. SHS has served as a speaker for BrainsWay (branded) and PsychU.org (unbranded, sponsored by Otsuka). SHS owns stock in BrainsWay (publicly traded) and Magnus Medical (not publicly traded). SHS owns intellectual property involving the use of functional connectivity to target TMS. No other authors report any disclosures. There has been no significant financial support for this work directly that could have influenced its outcome. This manuscript reflects the views of the authors only and not the Clinical TMS Society.
